1-dodecylpyridoxal (PLD)

05/15/2010 - "The three-dose regimen was used in confirmatory studies, which showed that IL-PLD produced significantly greater tumor volume reduction and enhanced survival versus PLD. "
01/01/2014 - "In summary, these data define a PKC-driven oncogenic signaling pathway that requires both PLD and mTOR, and suggest that inhibitors of PLD or mTOR would be beneficial in cancers where PKC overexpression is a contributing or driving factor."
10/01/2010 - "Seven of the 12 patients underwent further assessment of LVEF by echocardiography or multiple gated acquisition scan, which revealed a stable or improved ejection fraction.PLD is cardiac safe for long-term treatment of metastatic solid tumors. "
08/01/2008 - "PLD has also been shown to improve time to tumor progression when used as maintenance therapy. "
08/01/2007 - "We sought to investigate the toxicity and efficacy of PLD in gynecologic cancer patients with CKD. "

08/01/2009 - "PLD is safe and effective in patients with relapsed ovarian cancer, even after numerous previous treatment regimens. "
09/01/2013 - "This phase I study evaluated the safety, tolerability, and biologic activity of SB-485232 administered in combination with PLD in subjects with recurrent ovarian cancer. "
01/01/2013 - "We performed a meta-analysis of randomized trials in order to elucidate the role of PLD in ovarian cancer. "
12/01/2006 - "The encouraging results prompted us to plan a subsequent clinical study of PLD against ovarian cancer."
11/01/2004 - "Several phase II studies showed promising activity of PLD in recurrent ovarian cancer patients with response rate ranging from 16 to 25%. "

12/27/2011 - "PLD is a safe and effective treatment for elderly breast cancer patients. "
04/01/2013 - "Based on our limited experience, PLD and CM may be reasonable options for further study for elderly vulnerable patients with endocrine nonresponsive breast cancer."
01/01/2010 - "This observational study supports the activity and tolerability of PLD in metastatic breast cancer as demonstrated in PLD clinical trials."
01/01/2007 - "This community-based observational study supports previous reports indicating that PLD at a median dose of < or =40 mg/m(2) every 4 weeks is an active, well-tolerated agent in non-selected, pretreated patients with metastatic breast cancer."
01/01/2006 - "The favorable safety profile observed in this study leads us to recommend the use of PLD 40 mg/m(2) every 4 weeks for patients with advanced breast cancer."

01/01/2014 - "Eventhough the end results of PLD action as relates to downstream signaling mechanisms are still currently being elucidated, invasion, a pre-requisite for metastasis, is directly affected by PLD. "
06/01/2012 - "PLD may be of potential benefit in the prediction of neck metastasis in PTMC."
06/01/2012 - "Univariate and multivariate analyses revealed high PLD as the only independent variable predictive of neck metastasis. "
06/01/2012 - "Patients with high PLD (>8.0) showed higher rates of neck metastases than low PLD (≤ 8.0) (74.0% vs 46.8%, p = .03). "
04/01/2010 - "On the other hand, PLD showed no correlation with regional metastasis. "

02/01/2013 - "Patient demographics, PLD dose, ADEs, use of supportive care interventions, disease progression, and survival were extracted. "
03/01/2008 - "Patients were treated with PLD at a dose of 20 mg/m(2) intravenously every 3 weeks until disease progression or the occurrence of intolerable side effects. "
01/01/2004 - "PLD was administered at the dose of 35 mg/m2 q21 until disease progression or unacceptable toxicity. "
04/01/2013 - "The retrospective analysis included medical records of ovarian cancer patients who were treated with PLD due to disease progression after prior therapy. "
09/20/2009 - "This international, phase III study randomly assigned 751 patients to receive either docetaxel 75 mg/m(2) (n = 373) or PLD 30 mg/m(2) followed by docetaxel 60 mg/m(2) every 21 days (n = 378) and continued until disease progression or prohibitive toxicity. "